Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 1/20 | 0.42 |
| ▸ | PPARA | Q07869 | 6/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | F10 | P00742 | 2/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | CASP1 | P29466 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | NAMPT | P43490 | 1/20 | 0.37 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.37 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22008651 | 0.92 | CYP17A1 (0.46) | CYP17A1PPARADRD2F10MAPK14 | |
| SCHEMBL22009250 | 0.82 | CYP17A1 (0.46) | CYP17A1PPARADRD2F10MAPK14 | |
| SCHEMBL22009251 | 0.81 | CYP17A1 (0.42) | CYP17A1PPARADRD2F10MAPK14 | |
| SCHEMBL18538982 | 0.79 | KDM4E (0.51) | CYP17A1MAPTKDM4EHIF1A | |
| SCHEMBL22009252 | 0.76 | CYP17A1 (0.41) | CYP17A1PPARADRD2F10MAPK14 | |
| SCHEMBL245094 | 0.75 | CYP17A1 (0.61) | CYP17A1PPARADRD2MAPK14NAMPT | |
| SCHEMBL13234660 | 0.75 | PPARA (0.59) | PPARADRD2NPC1RAB9AATM | |
| SCHEMBL8003930 | 0.73 | PPARA (0.49) | CYP17A1PPARADRD2MAPTS1PR1 | |
| SCHEMBL10068777 | 0.73 | MAPT (0.50) | MAPTKDM4ERAB9AATM | |
| SCHEMBL6920421 | 0.73 | PPARA (0.48) | CYP17A1PPARADRD2S1PR1S1PR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200157087-A1 | MACROCYCLIC COMPLEXES OF ALPHA-EMITTING RADIONUCLIDES AND THEIR USE IN TARGETED RADIOTHERAPY OF CANCER | CORNELL UNIVERSITY (US) | 2020-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200157087-A1 | MACROCYCLIC COMPLEXES OF ALPHA-EMITTING RADIONUCLIDES AND THEIR USE IN TARGETED RADIOTHERAPY OF CANCER | PSMA1, FOLH1, KLK3 | CYP17A1 1161/4885PPARA 1429/4885DRD2 3095/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.